Warfarin and other 'anti'-vitamin K anticoagulants: Pharmacodynamics and clinical use

American Journal of Therapeutics

Volumn 3, Issue 11, 1996, Pages 771-783

  Freedman, Michael D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

antivitamin K agents; INR; interactions; thrombosis prophylaxis; thrombosis treatment; warfarin

Indexed keywords

ACENOCOUMAROL; ANISINDIONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; CARBAMAZEPINE; CIMETIDINE; CLOFIBRATE; DICOUMAROL; DIFLUNISAL; DIPHENADIONE; DISOPYRAMIDE; ERYTHROMYCIN; IBUPROFEN; KETOPROFEN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; PARACETAMOL; PENICILLIN G; PHENINDIONE; PHENPROCOUMON; PONALRESTAT; PROTEIN C; PROTEIN S; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; TOLMETIN; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; AORTA VALVE REPLACEMENT; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTRAHEPATIC CHOLESTASIS; INTRAVENOUS DRUG ADMINISTRATION; MITRAL VALVE REPLACEMENT; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SKIN NECROSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0030425662     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199611000-00007     Document Type: Review

References (84)

1. Schofield FW: A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover. Can Vet Rec 1924;3:74-78.
2. Link KP: Discovery of dicumarol and its sequels. Circulation 1959;19:97-107.
3. Huebner CF, Link KP: Studies on the hemorrhagic sweet clover disease. J Biol Chem 1941;138:529-534.
4. Butt HR, Allen EV, Bollman JL: A preparation from spoiled sweet clover (3,3′-methylene-bis-4 hydroxycoumarin) which prolongs coagulation time of blood: preliminary report of experimental and clinical studies. Mayo Clin Proc 1941;16:388-395.
5. O'Reilly RA, Levy G: Kinetics of the anticoagulant bishydroxycoumarin in man. Clin Pharmacol Ther 1970; 11:378-384.
6. O'Reilly RA: Studies on the optical enantiomers of sodium warfarin in man. Clin Res 1973;21:197A.
7. O'Reilly RA, Aggeler PM, Leong LS: Studies on the coumarin anticoagulant drugs: pharmacodynamics of warfarin in man. J Clin Invest 1963,42:1542-1551.
8. Nelsestuen GL, Zytkovicz TH, Howard JB: The mode of action of vitamin K: identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974;249:6347-6350.
9. Freedman MD: Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992;32:196-209.
10. O'Reilly RA: Studies on the optical enantiomers of sodium warfarin in man. Clin Res 1973;21:197A.
11. Green D: Protein C and S, In Clinical Thrombosis (Eds., Kwaan HC, Samama MM), CRC Press, Boca Raton, FL, 1989, p. 244.
12. Hirsh J, Poller L, Deykin D, Levine M, Dalen JE: Optimal therapeutic range for oral anticoagulants. Chest 1989; 95(Suppl):5S-11S.
13. Hauser VM, Rozek SL: Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharmacol 1986;20(12):964-967.
14. Askey JM: Hemorrhage during long term anticoagulant drug therapy. I. Intracranial hemorrhage. Calif Med 1966;140:6-10.
15. Koch-Wesler J: Coumarin necrosis. Ann Intern Med 1986;68:1365-1366.
16. Cole MS, Minifee PK, Wolma FJ: Coumarin necrosis - a review of the literature. Surgery 1988;103(3):271-277.
17. Rose VL, Kwaan HC, Williamson K, Hoppensteadt D, Walenga J, Fareed J: Protein C antigen deficiency and warfarin necrosis. Am J Clin Pathol 1986;86:653-655.
18. Rey AM, Gums JG: Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration. DICP 1991;25(7-8):745-746.
19. Janchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U: Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978;5:437-440.
20. Woo KS, Chan K, Pun CO: The mechanisms of warfarin-disopyramide interactions. Circulation 1987;76(4):520.
21. Freedman MD, Olatidoye AG: Clinically significant drug interactions with the oral anticoagulants. Drug Safety 1994;10(5):381-394.
22. Seelers EM, Koch-Weser J: Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clin Pharmacol Ther 1970;11:524.
23. Sioris LJ, Weibert RT, Pentel PR: Potentiation of warfarin anticoagulation by sulfisoxazole. Arch Intern Med 1980; 140(4)546-547.
24. Tilstone WJ, Gray JM, Nimmo-Smith RH, Lawson DH: Interaction between warfarin and sulphamethoxazole. Postgrad Med J 1977;53(621):388-390.
25. Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen: Sulfamethizole induced inhibition of diphenylhydantion, tolbutamide, and warfarin metabolism. Clin Pharmacol Therapeut 1975;17:731-734.
26. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Mltely CH, Goulart DA: The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Therapeut 1986;39(1):15-24.
27. Bijornsson TD, Meffin PJ, Swezey S, Blaschke TF: Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. J Pharmacol Exp Therapeut 1979;210(3):316-321.
28. O'Reilly RA: Dynamic interactions between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther Mar 1981;29(3):332-226.
29. O'Reilly RA: The steroselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295(7):354-357.
30. Hemimark LD, Winkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly: The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Therapeut 1992;51(4):398-407.
31. O'Reilly RA: Ticrynafen-racemic warfarin interactions: hepatotoxic or steroselective? Clin Pharmacol Therapeut 1982;32(3):356-361.
32. Silver BA, Bell WR: Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med 1979;90:348-349.
33. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O: Steroselective interaction of omeprazole with warfarin in healthy men. Drug Monitor 1989;11(2):176-184.
34. O'Reilly RA: Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984;144(5):989-991.
35. Blickstein D, Shaklai M, Inbal A: Warfarin antagonism by avocado. Lancet 1991;337:914-915.
36. Schary WL, Lewis RJ, Rowland M: Warfarin-phenylbutazone interaction in man, a long term multiple dose study. Res Commun Chem Pathol 1975;10(4):663-672.
37. Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Mltely CH, Goulart DA: The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Therapeut 1986;39(1):15-24.
38. Denbow CE, Fraser HS: Clinically significant hemorrhage due to warfarin-carbamazepine. South Med J 1990;83(8):981.
39. Udall JA: Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 1975;1:67-71.
40. Kates RE, Yee YG, Kirsten EB: Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Therapeut 1987;42(3):305-311.
41. 1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Hemostas 1984;51:358-361.
42. Qureshi GD, Reinders TP, Swint JJ, Slate MB: Acquired warfarin resistance and weight reducing diet. Arch Intern Med 1981;141(4):507-509.
43. Lutomski DM, Palascak JE, Bower RH: Warfarin resistance associated with intravenous lipid administration. J Parent Ent Nutr 1987;11:316-318.
44. Hume R: Interaction of ascorbic acid and warfarin. JAMA 1972;219:1479.
45. Corrigan JJ: The effect of vitamin E on warfarin-induced vitamin K deficiency. Ann NY Acad Sci 1982;393:361.
46. Bartle WR, Blakely JA: Potentiation of warfarin anticoagulation by acetaminophen. JAMA 1991;265(10):1260.
47. Justice JL, Kline SS: Analgesics and warfarin. A case that brings up questions and cautions. Postgrad Med 1988; 83(5):217-218.
48. Schrogie JJ, Solomon HM: The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate and norethandrolone. Clin Pharmacol Therapeut 1967;8:70.
49. Imperiale TF, Speroff T: A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271(22):1780-1784.
50. Paiement GD, Desautels C: Deep vein thrombosis: prophylaxis, diagnosis and treatment - lessons from orthopedic studies. Clin Cardiol 1990;13:V119-V222.
51. Taberner DA, Poller L, Burslem RW, Jones JB: Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. Br Med J 1978;1:272-274.
52. Francis CW, Marder VJ, McCollister E, Yaukoolbodi S: Two-step warfarin therapy. JAMA 1983;249:374-378.
53. Poller L, McKernan A, Thompson JM, Elstein M, Hirsch PJ, Jones JB: Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309-1312.
54. Harris WH, Salzman EW, DeSantis RW, Coutts RD: Prevention of venous thromboembolism following total hip replacement: Warfarin vs dextran 40. JAMA 1972;220: 1319-1322.
55. Powers PJ, Gent M, Jay RM: A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771-774.
56. Balderston RA, Graham TS, Booth RE, Rothman RH: The prevention of pulmonary embolism in total hip arthroplasty. Evaluation of low-dose warfarin therapy. J Arthroplasty 1989;4(3):217-221.
57. Haake DA, Berkman SA: Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis. Clin Orthop 1989;242:212-231.
58. Paiement G, Wessinger SJ, Waltman AC, Harris WH: Low dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty 1987;2:23-26.
59. Levine M, Hirsh J, Gent M, et al: Very low dose warfarin reduces thromboembolism in patients with metastatic breast cancer receiving chemotherapy. Lancet 1994;343: 886-889.
60. Hull R, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, McLoughlin D, Armstrong P: Warfarin sodium versus low-dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979;301:855-858.
61. Hull R, Delmore T, Carter C, Hirsch J, Genton E, Gent M, Turpie G, McLaughlin D: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194.
62. Hull R, Hirsch J, Jay R, Carter C, England C, Gent M, Turpie AGG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681.
63. Coulshed N, Epstein EJ, McKendrick, Galloway RW, Walker E: Systemic embolism in mitral valve disease. Br Heart J 1970;32:26-34.
64. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL: The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981;47:525-531.
65. Robicsek F, Harbold NB: The management of the patient with a prosthetic heart valve. Coll Works Cardiolpulm Dis 1975;20:87-105.
66. Edmunds LH: Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987;44(4): 430-345.
67. Lytle BW, Cosgrove DM, Loop FD, Taylor PC, Gill CC, Golding LAR, Goormastic M, Groves LK: Replacement of aortic valve combined with myocardial revascularization: determinants of early and late risk for 500 patients, 1967-1981. Circulation 1983;68(6):1149-1162.
68. Horstkotte D, Korfer R, Seipel L, Bircks W, Loogen F: Late complications in patients with Bjork-Shiley and St. Jude medical heart valve replacement. Circulation 1983; 68(Suppl 2):175-184.
69. Pipkin RD, Buch WS, Fogarty T: Evaluation of aortic valve replacement with a porcine xenograft without long-term anticoagulation. J Thorac Cardiovasc Surg 1976;71:179-185.
70. Hetzer R, Hill JD, Kerth WJ, Ansbro A, Adappa AG, Rodvien R, Kamm B, Gerbode F: Thromboembolic complications after mitral valve replacement with Hancock xenograft. J Thorac Cardiovasc Surg 1978;75:651-656.
71. Limet R, Lepage G, Grondin CM: Thromboembolic complications with the cloth covered Starr-Edwards aortic prosthesis in patients not receiving anticoagulants. J Thorac Cardiovasc Surg 1977;23:529-533.
72. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
73. Peterson P, Boysen G, Godtfredsen J, Anderson ED, Anderson B: Placebo controlled, randomized trial of warfarin and aspirin for the prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;i:175-179.
74. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-355.
75. Final Report, Stroke Prevention in Atrial Fibrillation Study. Circulation 1991;84:527-539.
76. Assessment of short-term anticoagulation administration after cardiac infarction. Report of the working party on anticoagulant therapy in coronary thrombosis to the medical research council. Br Med J 1969;1:335-342.
77. Anticoagulants in acute myocardial infarction, results of a cooperative clinical trial. JAMA 1973;225:724-729.
78. Drapkin A, Merskey C: Anticoagulant therapy after acute myocardial infarction. JAMA 1972;222:541-548.
79. The E.P.S.I.M. Research Group: A Controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708.
80. Second Report of the Working Party on Anticoagulant Therapy in coronary thrombosis to the medical research council: an assessment of long-term anticoagulant administration after cardiac infarction. Br Med J 1964;2:837-843.
81. Elbert RV, Borden CW, Hipp HR, et al.: Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration Cooperative Study. J Am Med Assoc 1969;207:2263-2267.
82. Sixty Plus Reinfarction Study Research Group: A double blind trial to access long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-993.
83. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis Research Group: Effects of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
84. Vaitkus PT, Barnathan ES: Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993;22:1004-1009.